EP2307022A4 - Enhanced nsaid formulations - Google Patents

Enhanced nsaid formulations

Info

Publication number
EP2307022A4
EP2307022A4 EP08845326A EP08845326A EP2307022A4 EP 2307022 A4 EP2307022 A4 EP 2307022A4 EP 08845326 A EP08845326 A EP 08845326A EP 08845326 A EP08845326 A EP 08845326A EP 2307022 A4 EP2307022 A4 EP 2307022A4
Authority
EP
European Patent Office
Prior art keywords
enhanced
nsaid formulations
nsaid
formulations
enhanced nsaid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08845326A
Other languages
German (de)
French (fr)
Other versions
EP2307022A1 (en
Inventor
Fahkreddin Jamali
Habashi Ali Aghazadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Equitech Corp
Original Assignee
Equitech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equitech Corp filed Critical Equitech Corp
Publication of EP2307022A1 publication Critical patent/EP2307022A1/en
Publication of EP2307022A4 publication Critical patent/EP2307022A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP08845326A 2007-10-31 2008-10-30 Enhanced nsaid formulations Withdrawn EP2307022A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98405807P 2007-10-31 2007-10-31
US99117907P 2007-11-29 2007-11-29
PCT/CA2008/001919 WO2009055925A1 (en) 2007-10-31 2008-10-30 Enhanced nsaid formulations

Publications (2)

Publication Number Publication Date
EP2307022A1 EP2307022A1 (en) 2011-04-13
EP2307022A4 true EP2307022A4 (en) 2011-08-24

Family

ID=40590492

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08845326A Withdrawn EP2307022A4 (en) 2007-10-31 2008-10-30 Enhanced nsaid formulations

Country Status (2)

Country Link
EP (1) EP2307022A4 (en)
WO (1) WO2009055925A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2804594A1 (en) * 2012-01-18 2014-11-26 Mahmut Bilgic Formulations comprising diclofenac as the active agent
EP3749290A4 (en) * 2018-01-29 2022-01-26 Jonathan Sackner-Bernstein Methods for dopamine modulation in human neurologic diseases
CN115998724B (en) * 2023-03-28 2023-06-16 中国人民解放军军事科学院军事医学研究院 New application of ibuprofen in anti-hallucination effect medicament

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012524A1 (en) * 1997-09-11 1999-03-18 Nycomed Danmark A/S MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
EP1285655A1 (en) * 2000-04-11 2003-02-26 Sankyo Company, Limited Stabilized pharmaceutical compositions containing calcium channel blockers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6357521A (en) * 1986-08-28 1988-03-12 Taisho Pharmaceut Co Ltd Oral preparation
JP2906528B2 (en) * 1990-02-14 1999-06-21 大正製薬株式会社 Solid preparation for internal use with enhanced absorption
US20020192161A1 (en) * 2001-04-10 2002-12-19 Fahkreddin Jamali Animal model for evaluating analgesics
US20030026834A1 (en) * 2001-04-10 2003-02-06 Fahkreddin Jamali NSAIDs composition containing tartaric acid
GB0113839D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
CA2565941A1 (en) * 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
EP1817021A1 (en) * 2004-11-03 2007-08-15 Equitech Corporation Nsaid compositions exhibiting clinical superiority

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012524A1 (en) * 1997-09-11 1999-03-18 Nycomed Danmark A/S MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
EP1285655A1 (en) * 2000-04-11 2003-02-26 Sankyo Company, Limited Stabilized pharmaceutical compositions containing calcium channel blockers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009055925A1 *

Also Published As

Publication number Publication date
EP2307022A1 (en) 2011-04-13
WO2009055925A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
GB2435419B (en) Formulations
GB0711656D0 (en) Formulations
GB0716385D0 (en) Formulations
EP2046930A4 (en) Rhamnolipid-based formulations
GB0605780D0 (en) Formulations
EP2106318A4 (en) Flux formulations
GB0815435D0 (en) Formulations
ZA200908969B (en) Formulations
GB2459691B (en) Formulations
GB0823269D0 (en) Formulations
GB0618697D0 (en) Formulations
GB0711957D0 (en) Formulations
GB0809979D0 (en) Formulations
GB0610336D0 (en) Formulations
GB0821789D0 (en) Formulations
EP2307021A4 (en) Formulations
GB0810232D0 (en) Formulations
EP2307022A4 (en) Enhanced nsaid formulations
GB0718404D0 (en) Formulations
GB0705179D0 (en) Formulations
GB0921378D0 (en) Formulations
GB0916030D0 (en) Formulations
GB0822171D0 (en) Temisartan formulations
GB0710346D0 (en) Formulations
GB0701993D0 (en) Formulations

Legal Events

Date Code Title Description
PUAJ Public notification under rule 129 epc

Free format text: ORIGINAL CODE: 0009425

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100902

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110725

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20110719BHEP

Ipc: A61K 47/12 20060101ALI20110719BHEP

Ipc: A61K 47/02 20060101ALI20110719BHEP

Ipc: A61K 31/196 20060101ALI20110719BHEP

Ipc: A61K 31/192 20060101ALI20110719BHEP

Ipc: A61K 31/166 20060101ALI20110719BHEP

Ipc: A61K 31/135 20060101ALI20110719BHEP

Ipc: A61K 31/454 20060101AFI20110719BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120222